Nanotechnology for excipients (or “nanotech”) is the use of matter on an atomic, molecular, and supramolecular scale for industrial purposes. The National Nanotechnology Initiative defined nanotechnology as the manipulation of matter with at least one dimension sized from 1 to 100 nanometers.
Pharma Excipients
Nanotechnology
Smart nano-in-microparticles to tackle bacterial infections in skin tissue engineering
Chronic wounds (resulting from underlying disease, metabolic disorders, infections, trauma, and even tumours) pose significant health problems. In this work, microparticles, based on polysaccharides (maltodextrin or dextran) and amino acids, and doped with antibacterial nanoparticles (CuO or ZnO…
Read More...
Read More...
Nanosuspensions as carriers of active ingredients: Chemical composition, development methods, and…
Nanosuspensions (NSps) are colloidal dispersions of particles that have the potential to solve the delivery problems of active ingredients associated with their low solubility in water or instability due to environmental factors. It is essential to consider their chemical composition and preparation…
Read More...
Read More...
Chitosan nanoparticles and based composites as a biocompatible vehicle for drug delivery: A review
The shellfish processing industry is one of the largest growing industries across the globe with a market size of around USD 62B. However, it also leads to a significant environmental issue as it produces >80,000 tons of waste shells globally. Unfortunately, the slow degradation of this waste…
Read More...
Read More...
Silica nanoparticles: A review of their safety and current strategies to overcome biological…
Abstract
Silica nanoparticles (SNP) have gained tremendous attention in the recent decades. They have been used in many different biomedical fields including diagnosis, biosensing and drug delivery. Medical uses of SNP for anti-cancer, anti-microbial and theranostic applications are especially…
Read More...
Read More...
Aptamer-modified chitosan-capped Mesoporous silica nanoparticles for co-delivery of cytarabine and…
Abstract
In this study, surface modified mesoporous silica nanoparticles (MSNs) were prepared for the targeted delivery of the anticancer agents, daunorubicin (DNR) and cytarabine (CTR), against K562 leukemia cancer cell lines. The MSNs were surface-modified with pH-sensitive chitosan (CS) to…
Read More...
Read More...
Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment
This review evaluates the literature on nanoparticle-based drug delivery systems for cancer treatment and assesses their efficacy. Nanoparticles have shown potential for improving anticancer agent delivery, reducing systemic toxicity, and enhancing therapeutic outcomes. Extensive studies have shown…
Read More...
Read More...
A coronavirus-mimic mesoporous silica nanosystem enables efficient targeted delivery of siRNA for…
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been a threat to human beings' health. However, there is still a lack of effective specific antiviral drugs for SARS-CoV-2 at present, which calls for the exploitation of new potent and safe therapeutic agents.…
Read More...
Read More...
Niosomes for nose-to-brain delivery: A non-invasive versatile carrier system for drug delivery in…
Neurodegenerative diseases (NDDs) significantly contribute to morbidity and mortality worldwide. The suboptimal effect of currently used therapeutic approaches administered via oral and parenteral routes for treatment of NDDs is mainly due to poor drug delivery to the brain. The blood-brain barrier…
Read More...
Read More...
Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies
Abstract
The World Health Organization identifies tuberculosis (TB), caused by Mycobacterium tuberculosis, as a leading infectious killer. Although conventional treatments for TB exist, they come with challenges such as a heavy pill regimen, prolonged treatment duration, and a strict schedule,…
Read More...
Read More...
Brain-Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha-Synuclein Aggregation and…
Monoclonal antibodies (mAbs) hold promise for treating Parkinson's disease (PD), but their therapeutic use is hindered by poor delivery to the brain. In this study, we demonstrate that brain-targeted liposomes (BTL) enhance the delivery of mAbs across the blood-brain-barrier (BBB) and into neurons,…
Read More...
Read More...